Women's Health Initiative Study of Cognitive Aging (WHISCA)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified February 2008 by Wake Forest University.
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by:
Wake Forest University
ClinicalTrials.gov Identifier:
NCT00631332
First received: February 28, 2008
Last updated: NA
Last verified: February 2008
History: No changes posted

February 28, 2008
February 28, 2008
July 1999
September 2007   (final data collection date for primary outcome measure)
Does HT protect against age-associated memory and cognitive longitudinal decline in women age 65 and older as measured over time by a series of cognitive tests administered annually? [ Time Frame: Annual assessment done annually. ] [ Designated as safety issue: No ]
Same as current
No Changes Posted
To determine the long-term effects of HT on changes in memory, other cognitive functions, and affect; and to investigate predictors of the transitions between normal aging and mild cognitive impairment and mild cognitive impairment and dementia. [ Time Frame: measured over lift of the study ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Women's Health Initiative Study of Cognitive Aging
Effects of Hormone Replacement Therapy on Cognitive Aging: Women's Health Initiative Study of Cognitive Aging (WHISCA)

The Women's Health Initiative Study of Cognitive Aging (WHISCA) is a two-armed, randomized, placebo controlled, clinical trial designed to assess the efficacy of postmenopausal hormone therapy (HT) on age related changes in specific cognitive functions. WHISCA is an ancillary study to the Women's Health Initiative (WHI) and the WHI Memory Study (WHIMS) and has enrolled 2303 women aged 66 to 84 years who did not meet the criteria for dementia. WHISCA is investigating the effects of hormone therapy on rates of change over time in memory, other aspects of cognition (language, attention, spatial ability), motor function, and mood.

Objectives

  • Does HT protect against age-associated memory and cognitive longitudinal decline in women age 65 and older?
  • What is the rate of change in memory and other cognitive abilities in women receiving HT compared to women receiving placebo?
  • Does the addition of progesterone to HT modify the effects of estrogen on memory and other cognitive abilities?
Not Provided
Observational
Not Provided
Not Provided
Not Provided
Non-Probability Sample

A subset of women who were enrolled in the Women's Health Initiative Memory Study (WHIMS), who are at least 65 years old and not diagnosed with any type of dementia.

Healthy
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
2303
June 2008
September 2007   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Enrolled in WHIMS
  • At least 65 years old
  • Not diagnosed with dementia

Exclusion Criteria:

  • Women younger than 65 years of age
  • Have dementia
  • not enrolled in WHIMS
Female
65 Years to 90 Years
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00631332
NO1-AG-9-2115
Yes
National Institute of Health/National Institute of Aging
Wake Forest University
Not Provided
Not Provided
Wake Forest University
February 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP